Cambridge spinout Crescendo Biologics has leveraged its transgenic protein discovery platform to license out an antibody to biopharmaceutical developer Zai Lab.
Crescendo Biologics, a UK-based immunotherapy develop spun out from University of Cambridge, has agreed to license out one of its antibodies to biopharmaceutical developer Zai Lab.
The exclusive worldwide licence allows Zai Lab to develop, commercialise and manufacture an antibody treatment for inflammatory conditions based on Crescendo’s Humabody transgenic protein discovery platform.
Zai Lab expects to file for an investigational new drug in 2019 as a target for skin disorder psoriasis.
Transgenics involves the transfer of genetic material from another species, mice in…